Search
Now showing items 1-4 of 4
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
(Elsevier, 2021-12)
Abstract
The clinical outcome of patients with human epidermal growth factor receptor 2 (HER2) amplified breast carcinoma (BC) has improved with the development of anti-HER2 targeted therapies. However, patients can ...
Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting
(Springer, 2021-06)
Abstract
Background: Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status (PS) are underrepresented in clinical trials. We ...
Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?
(Baishideng Publishing Group, 2021-01)
Abstract
Thoracic radiotherapy (TRT) is one of the main treatments in limited-stage small cell lung cancer (LS-SCLC). Hyperfractionated TRT (45 Gy, 1.5 Gy twice daily) has been the standard of care (SOC) since Turrisi and ...
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
(Elsevier, 2020-09)
Abstract
Background: Nivolumab was the first anti-programmed cell death 1 drug approved in Argentina for non-small-cell lung cancer treatment in the second-line setting.
Materials and methods: The present study was a ...